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ABSTRACT 
Objective: Parameters in the oil pre-concentrate which can affect the solvent capacity of the resultant dispersion such as, oil-cosurfactant ratio, type 
of surfactant used in the system, the inclusion of water soluble co-solvents and the solubilization capacity of native surfactants such as, bile salts and 
lecithin were studied in an attempt to circumvent crystallization of drug during its passage in the gut.  
Methods: Different types of self-emulsifying systems representing type II, IIIA and IIIB, were used to probe the influence of the various physicochemical 
properties of the resultant dispersions on the fate of dissolved model lipophilic drug. This was achieved by studying emulsification behavior of lipid systems 
in fed and fasted biological fluids, analyzing solubilization/drug crystallization kinetics and oil droplet diameter measurement.  
Results: Self-micro-emulsifying lipid systems lost solvent capacity on dispersion and were not able to keep the drug in solution at equilibrium. 
Miglyol 812/Imwitor ratio in the pre-concentrate mixture appeared to influence the kinetics of drug crystallization. Pre-microemulsion systems 
containing Tagat TO dispersions were found to hold more drugs in solution at equilibrium than in the case of systems containing Cremophor RH40. 
The inclusion of as little as 10-20% PEG in the lipid mixture accelerated drug precipitation. Bile salt-lecithin mixed micelles appears to some extent 
enhance the solubilization capacity of these systems after dispersion 
Conclusion: Solvency of emulsions formed by self-emulsifying drug delivery in various emulsification media is a crucial parameter influencing the 
fate of dissolved drug after the dispersion of the formulations.  
Keywords: SEDDS, SMEDDS, Lipid formulations, Medium chain mono-and glycerides, Poorly water-soluble compounds 




Lipid-based drug delivery systems (LBDDS) including self-
emulsifying drug delivery systems (SEDDS) or self-micro-
emulsifying drug delivery system (SMEDDS) are isotropic mixtures 
of oils and non-ionic surfactants which upon gentle agitation in 
water produce (o/w) dispersions of droplets<5 µm [1] or between 5 
and 140 nm [2], respectively. Due to high hydrophilic content of 
SMEDDS which include materials such as; polar oils including mixed 
mono and/or di-medium chain glycerides, high HLB nonionic 
surfactants (>12), and hydrophilic co-solvents, these oil vehicles are 
considered more hydrophilic than SEDDS. Oil-based systems were 
classified into type I, II, IIIA, IIIB and IV, based on various 
physicochemical factors such as; the hydrophilicity of the oil 
mixture, the particle size of the resultant dispersion and the 
formulation digestibility [3-4]. Type IV formulations do not contain 
natural lipids and represent the most hydrophilic formulations. 
Hydrophilicity of the lipid mixture increases by moving from type 1 
lipid class system to type 4. The reformulation of cyclosporine A as 
Neoral® is an archetypal example of a Type III system [5]. The HIV 
protease inhibitor amprenavir (Agenerase®) which contains TPGS 
as a surfactant and PEG 400 and propylene glycol as co-solvents [6] 
is an example of Type IV formulations which do not contain natural 
lipids and thus represent the most hydrophilic formulations. 
Amprenavir (Agenerase®) was succeeded though by a pro-drug, 
fosamprenavir [7]. These lipid formulations are thoroughly 
characterized and studied, and hence represent one of 
quintessential approach for the bioavailability enhancement poorly-
water-soluble compounds; especially class II drugs. The past nearly 
4 decades from 1975 through 2013 have shown rampant growth in 
utilizing solubilization techniques, accounting on average for around 
6% of all new molecular entities (NMEs) approved [8]. Furthermore, 
the same study has shown that LBDDS are the most widely used 
solubilization platform. It is estimated that LBDDS oral drug 
products account for 2–4% of all commercially available drug 
products according to a study by Strickley in 2007 [9]. According to 
various drug databases and reviews, there are more than 36 
different oral LBDDS on the market of 27 unique drug molecules that 
were FDA approved by FDA [10-12]. Some of the most recent LBDDS 
products include; Isotretinoin (Absorica®, by Cipher 
pharmaceuticals a reformulation of isotretinoin (Accutane); New 
drug application year NDA; 2012) [13], Enzalutamide (Xtandi®, 
NDA; 2012) [14], Nintedanib (Ofev®, NDA; 2014) [15] and 
Calcifediol (Rayaldee™, NDA; 2016) [16].  
In the design of successful lipid formulations with maximize the 
bioavailability; key elements in the lipid composite have to be 
optimized [17-18]. Nonetheless, crystallization of the drug in the 
lumen of the gut depends on the hydrophilicity of oil system; log P of 
the drug and the solubilization capacity of native surfactants (bile 
salt-lecithin mixed micelles) to maintain the drug in solution during 
digestion. The medium into which the drug must dissolve has a great 
influence on its solubility hence; suitable media which satisfactorily 
simulate the physiological conditions are needed. In the GI tract, the 
solubility of the drug is a function of aqueous solubility, crystallinity, 
drug lipophilicity, pKa
MATERIALS AND METHODS 
 in relation to the pH profile of GI tract, 
solubilization by native surfactants (such as bile salts and lecithin) 
and ingested food components. Four suitable media have been 
suggested to simulate the composition of proximal GI tract [19]: SGF 
plus surfactant for fasted state stomach; long-life milk (3.5% fat) for 
fed state stomach; FaSSIF and FeSSIF for fasted and fed state small 
intestine. Physicochemical properties of emulsions formed by 
various types of lipid systems which can influence drug 
solubilization were studied here in an attempt to probe the fate of 
dissolved drug after dispersion. 
Materials  
Miglyol 812 (medium chain triglyceride) and Imwitor 988 (C8/C10 
mono/diglycerides) were supplied by Condea Chemie GmbH. Tagat 
TO (PEG-(25)-glyceryl trioleate) was supplied by Goldschmidt AG, 
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Germany. Crillet 4 (Polyoxyethylene-(20)-sorbitan monooleate), also 
known as Tween 80 or polysorbate 80, was supplied by Croda 
Chemicals. Cremophor RH 40 (polyoxyethylene-(40)-hydrogenated 
caster oil) and Cremophor EL (polyoxyethylene-(35)-caster oil) 
were obtained from BASF Corporation. Hydrophilic co-solvents used 
in lipid formulations; Propylene Glycol (1,2,-Propanediol) and 
Polyethylene Glycol 400 were purchased from Sigma, UK; Ethanol 
96% w/w GPR, BDH Chemicals; Transcutol P® (diethylene glycol 
monoethyl ether or Ethoxydiglycerol) was obtained from Gattefossé 
Corporation and Glycofurol (α-Tetarahydro furanyl–w-hydroxy-poly 
(oxyethylene) was supplied by Roche, Switzerland. Methanol 96% 
v/v GPR, BDH Chemicals was used as a solvent for the analytical 
assays. Materials used to prepare the simulated fasted and fed state 
intestinal conditions (FaSSIF and FeSSIF); Na Taurcholate, Lecithin, 
and KCL were obtained from Sigma and KH2PO4 from BDH 
Chemicals. Dimethyl aminoazobenzene also was known as 
Dimethy Yellow was used in this study as a model drug of ‘poorly 
soluble’ weak base (log P of 4.52, pKa of 3.226 and S0
Methods 
= 
1.33µg/ml) and was purchased from Sigma, UK. All water used 
was milli Q water 
Preparation of the lipid mixtures 
Mixtures of oil, co-surfactant, and surfactants representing Type I, II, 
IIIA and IIIB were produced by accurately weighing ingredients into 
screw-capped glass vials with tight closures, see table 1. Mixtures 
were placed in a water bath at 50 °C for 2 min before the three 
components were thoroughly vortexed. Mixtures were then kept for 
24 h in a stability oven set up at 25°C for equilibrium. 
  
Table 1: Selected lipid formulations used to investigate the effect of oil composite on the solubility of DMY and the fate of drug after 
dispersion 
Lipid formulation Excipients (%w/w) 
Miglyol 812 Imwitor 988 Tagat TO Cremophor RH40, EL, or Crillet 4 PEG 400 
Type I 70 0 30  0 
Type II 49 21 30 0 0 
Type IIIA 42, 49, or 49 28, 21, or 21 0 30 0 
Type IIIB 0 30 0 30 40 
 
The solubility of the model drug in lipid formulations  
The model drug (Dimethyl Yellow) was added in excess (≈1g) to 
either lipid excipients or to lipid formulations. Lipid suspensions 
were then vortexed for 3 min and then stored for 24 h in a 
controlled temperature oven at 25°C to reach equilibrium (samples 
were vortexed in between). Oil suspensions were centrifuged at 
maximum speed (13000g) for 10 min. The clear saturated oil 
solution was then removed and assayed analytically by UV 
spectrophotometry using a double beam instrument (Perkin-Elmer 
Lamboda 7, UV/VIS Spectrophotometer) at λ max
FaSSIF and FeSSIF were prepared by first making the micellar 
solution which consists of bile salt (Na Taurcholate) and Lecithin (L-
α phosphatidylcholin) at a ratio of 3:1. To prepare the mixed 
micellar solution appropriate quantities of bile salt (15 mmol) and 
lecithin (3.75 mmol) were dissolved in 20 ml of solvent consisted of 
methanol and chloroform at a ratio of 2:3. The resultant clear 
solution was placed in a 500 ml Büchi flask and the solvent drawn 
off using rotary evaporator (Büchi Rotavapor R110). The flask was 
then attached to a vacuum line overnight to ensure the removal of 
any remaining chloroform. The clear film of bile salt and lecithin 
formed on the flask surface was subsequently dissolved in the 
appropriate buffer, see table 2 [19]. 
 of 407 nm.  
Preparation of the emulsification media (FaSSIF and FeSSIF) 
Self-emulsification of oil systems containing dissolved DMY 
Lipid systems containing 4% of the model drug were emulsified 
using 1 gm of the lipidic mixture in 100 ml of different emulsification 
media; water, FaSSIF or FeSSIF. Dispersions were emulsified at 37 °C 
for 15 min by gentle agitation at 100 oscillations/minute. The 
solubility of Dimethyl Yellow in the aqueous dispersions was 
monitored with time. Measurements were performed in triplicate 
values are expressed as mean values of all data ± standard error. 
 
Table 2: Composition of two physiological media used to simulate fasted state and fed state intestinal conditions 
Fasted state simulated intestinal 
fluid (FaSSIF) 
Fed state simulated intestinal 
fluid (FeSSIF) 
pH 6.5 pH 5 
Osmolarity 270±10 m Osmol Osmolarity 635±10 m Osmol 
Na Taurcholate  3 mmol Na Taurcholate 15 mmol 
Lecithin 0.75 mmol Lecithin 3.75 mmol 
KH2PO 3.9g 4 Acetic Acid 8.65g 
KCL 7.7g KCL 15.2g 
NaOH qs pH 6.5 NaOH qs pH 5 
Mili1 Q water qs 1 liter Mili Q water qs 1 liter 
 
Particle size analysis  
Quasi-elastic light scattering (QELS, Malvern model LO-C photon 
correlation spectrometer) was used to analyze samples of 
submicron dispersions. 
RESULTS AND DISCUSSION 
The solubility of dimethyl yellow (DMY in the lipid matrix) 
One commonly used approach to improve absorption is to solubilise 
the drug in a water-soluble cosolvent, such as polyethylene glycol 
which may have sufficient solvent capacity for drug administration 
as a unit dose. Yet, it is likely that the drug will crystallize on dilution 
of the cosolvent in the lumen of the gut. Unlike water-miscible 
cosolvent systems, lipids due to their immiscibility with water can 
maintain poorly soluble drugs in solution. However, when oil 
systems cannot provide sufficient solvent capacity for the drug in 
the unit dosage form, water-miscible cosolvents can be included in 
the pre-concentrate formulation. Therefore, verification of drug 
solubilization in the excipient matrix with a suitable assay for the 
drug is a crucial pre-formulation step that should be undertaken to 
assess the viability of any lipid system.  
The solubility of DMY (a lipophilic model drug) in various water-
miscible cosolvents and also in different types of lipid-based 
formulations is depicted in fig. 1. Maximum solubilization of DMY 
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was obtained in Glycofurol followed by Transcutol. An 
approximately 2.5 fold decrease in the DMY solubility was observed 
in Polyethylene glycol 400 system vis-à-vis Glycofurol. The solubility 
of DMY, on the other hand, was the lowest in the case of Propylene 
glycol system. However, the solubility of DMY in various lipid 
formulae representing Type I, II, IIIA and IIIB (see, table 1 for 
composition) or in Miglyol 812 (source of triglycerides) was ≈ 40 
mg/g. Whereas, DMY solubility measured 20 mg/g in the case of 
more polar oil; Imwitor 988.  
Considering the cosolvent solubilization power (σ) concept in the 
log-linear model proposed by Yalkowsky and coworkers [20-22], we 
can retrospectively work out σ for DMY in the various cosolvent 
systems which were used in this study. The log-linear model 
describes an exponential increase in the solubility of non-polar 
drugs with a linear increase in cosolvent concentration. This is 
presented in the following equation:  
Log S tot  = log S w+σ X f c
Where S
 (Eq. 1) 
 tot is the total solubility of the drug in the cosolvent-water 
mixture, S w is its water solubility, σ is the cosolvent solubilization 
power for the particular cosolvent-solute system, and f c is the volume 
fraction of cosolvent in the aqueous mixture. For this study σ was 
obtained from the log (S tot/S w) considering fc = 1 as no water was 
included in the cosolvent system. Table 3 lists the cosolvent 
solubilization power (σ) obtained from Eq 1 and the partition 
coefficient (log P) of the considered cosolvent systems. The log P 
values were obtained by means of the ClogP software package. The log 
P denotes the polarity of the cosolvent system. Table 3 suggests that 
the higher the log P of the cosolvent, the lower the polarity and hence 
the higher the solubilization power. The following order is observed: 
log PGlycofurol>log PTranscutol>log PPEG 400>log PG
  
. The least polar cosolvent, 
Glycofurol, has the maximum solubilization power for DMY (σ = 4.8), 
and the highest polar cosolvent, PG, has the lowest value (σ = 3.19). 
 
Fig. 1: Apparent solubility of DMY in various hydrophilic cosolvents, lipid excipients and oil formulae representing lipid class systems 
type II, IIIA and IIIB; see table 1 for. The drug was added in excess to these systems and left to equilibrate at 25 °C for 24h 
 
Table 3: The effect of cosolvent polarity on the cosolvent solubilization power (σ) for DMY in PG, PEG 400, Transcutol and Glycofurol 
(sorted by increasing log P) 
Cosolvent system Cosolvent log P Solubilization power (σ) Solubility of DMY mg/g 
Propylene glycol -0.92 3.19 2.06±0.002 
Polyethylene glycol 400 -0.88 4.36 30.46±0.42 
Transcutol -0.15 4.66 60.99±1.54 
Glycofurol -0.04 4.80 83.53±1.69 
*Each value represents mean±S. D (n=3). 
 
This is expected since less polar cosolvents can reduce self-
association than polar cosolvents as they have a better affinity for 
the non-polar compounds. It is worth noting here that, Polyethylene 
glycol 400 has higher σ value than Propylene glycol albeit they both 
have close log P values. This might be due to the large area of 
interaction with the DMY in the case of PEG 400 due to the relatively 
high number of polyoxyethylene residues (an average of 9 residues 
per molecule). Furthermore, identical solubilization power of 4.5 
was found for these lipid systems, yet, with a lower value in the case 
of Imwitor 988 (σ = 4.2) as it is a more polar oil due to the 
monoglyceride content. On the other hand, the inclusion of PEG 400 
in the oil mixture to formulate Type IIIB did not, however, enhance 
the solubility of DMY as PEG 400 has a relatively low solubilization 
power. If a high DMY solubility is required, cosolvents with high 
solubilization power such as Glycofurol or Transcutol can be used.  
Physicochemical parameters influencing the solvency of 
dispersions formed by various lipid-based formulations  
Hydrophilicity of the lipid-vehicle: oil formulations Vs cosolvent 
systems 
Studies generally, in the field of lipid-based formulations, focus on 
investigating the effect of the drug on the physicochemical 
characteristics of the resultant dispersions in particular, emulsion 
droplet size as it is crucial for the enhanced bioavailability. Also, 
equilibrium phase behavior is being studied in the presence of the 
drug, especially if the drug has surface activity, in order to establish 
an empirical link between these effects incurred by the inclusion of a 
particular drug and emulsification [23]. Nonetheless, there have not 
been many reports which outline how the physicochemical 
properties of emulsions formed by SEDDS can influence the fate of 
dissolved drug after dispersion. We are investigating the effect of the 
solvent capacity of these dispersions on the solubilization behavior 
of the drug and how factors such as oil-cosurfactant ratio, type of 
surfactant and the inclusion of various cosolvents can influence this 
behavior in an attempt to circumvent the precipitation of drug.  
Photos presented in fig. 2 and 3 outline the effect of various types of 
either lipid-based formulations or cosolvent systems on the 
precipitation of drug after dispersion of the formulation. Fig. 2 
shows the aqueous dispersions of oil formulations in the presence of 
approximately 40 mg/g DMY representing Type II lipid-class system 
(bottles A and B), and Type IIIA (bottles C, D, and E), see table 1 for 
composition. In Type II lipid systems, the pre-concentrate mixture, 
which is composed of water-insoluble materials, was selected to 
from either a self-emulsified dispersion of particle size more than 
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250 nm or a microemulsion of particle size<100 nm, bottles A and B, 
respectively. On the other hand, various types of hydrophilic 
surfactants Cremophor RH40, EL or Crillet 4 were included in Type 
IIIA systems, bottles, C, D or E, respectively. Visual assessment of 
dispersions depicted in fig. 2 did not reveal any crystallization of 
DMY in the first 24 h. Nonetheless, dispersions which formed fine 
emulsions (bottles B and C) were subjected to further analytical 
assessment for several days in order to study the solubilization 
behavior of DMY with time in these systems. Furthermore, an 
instant crystallization of DMY occurred from the emulsification of 
either Imwitor 988/RH40-PEG 400 (30/30/40) system, an 
archetypal example of Type IIIB hydrophilic lipid formulations, or 




Fig. 2: Photograph of the effect of various lipid systems on the solubilization of DMY after the dispersion of the formulation. Bottles A to E 
represent dispersions of formulations representing type II and type IIIA lipid class system. 1g of each formulation containing 
approximately 40 mg DMY was allowed to emulsify in 100 ml water at 37 °C for 15 min. Dispersions were assessed visually and 
analytically for detecting any drug precipitation due to loss of solvent capacity 
 
 
Fig. 3: Photograph of the effect of either Type IIIB lipid class formulation (Imwitor 988/Cremophor RH40-PEG 400) or water-miscible 
cosolvent based systems (Glycofurol and Transcutol) on the solubilization of DMY after the dispersion of the formulation. 1g of each 
formulation was emulsified in the presence of DMY in 100 ml water at 37 °C for 15 min 
 
 
Fig. 4: Effect of hydrophilicity of the oil vehicle on the solubilization profiles of DMY with time. Lipid formulations representing Type II 
(●), I I IA (■) and I I IB (▲) and containing around 40 mg/g DMY were allowed to emulsify (1g) in 100 ml of water at 37 °C for 15 min. 
Dispersions were kept for various periods of time for probing drug precipitation. Bars represent standard errors (n = 3) 
Hasan et al. 




Fig. 5: Solubility of DMY in various surfactant-water mixtures as a function of surfactant concentration 
 
Type IIIB formulations generally produce the finest dispersions because 
of their high content of water-soluble solubilizing agents, viz. they 
contain more than 60% hydrophilic surfactant and/or water-miscible 
cosolvents [3]. Hence, the water-soluble components tend to diffuse 
away from the oil during dispersion and become dissolved in the 
aqueous phase. The result of this separation, which may be the driving 
force for emulsification by ‘diffusion and stranding’, is likely to be a loss 
of solvent capacity [17]. As a consequence, the drug is partially 
precipitated when the formulation disperses. This was also evident from 
the water-miscible cosolvent systems glycofurol and transcutol whereby, 
spontaneous crystallization of DMY occurred after dilution in the 
aqueous phase [24-25]. An example of a co-solvent formulation is 
vinorelbine (Navelbine®) [26]. The extent of precipitation will depend 
on the hydrophilicity of the lipid system, the particle size of the resultant 
dispersion, the contribution of the hydrophilic material (hydrophilic 
surfactant and/or cosolvent) to the solubilization of the drug within the 
formulation and the log P of the drug.  
Fig. 4 displays the effect of hydrophilicity of the lipid matrix, as 
controlled by the type of excipients included in the system, on the 
solubilization behaviour of DMY. The {Miglyol 812/Imwitor 988}-
Tagat TO at ratio of (70(70/30)30) is a pre-microemulsion Type II 
lipid mixture [17]. This type of formulation is composed of water-
insoluble materials i.e. a hydrophobic system. Hence, it is expected 
to retain its solvent capacity for the drug after dispersion. It is 
evident from the emulsification of this system in the presence of 
DMY that the solvency of the resultant dispersion was able to keep 
the drug in the super-saturated state for up to 3 d after the 
emulsification event. However, at equilibrium which can take up to 
five days, only 6 mg of DMY (15%) out of an initial dose of 
approximately 40 mg came out of solution. This limited amount of 
crystallized material after 5 d might be due to the fact that the 
system forms fine dispersion on emulsification of less than 100 nm 
so oil droplets which contain the dissolved drug will be highly 
exposed to the aqueous phase due to large surface area of contact 
and thus minimal crystallization has occurred. This process, 
however, might take long time to reach equilibrium as it was 
demonstrated. On the other hand, the self-emulsified type II class 
lipid-system which forms dispersion with particle size of>250 nm 
such as Miglyol 812/Tagat TO (bottle A, fig. 2) had shown no 
indication for DMY crystallization. This might be attributable to the 
relatively large droplet size whereby, DMY will be sequestered 
within the oil phase. Hence, there will be virtually minimal 
interaction between the non-polar compound and the water's 
hydrogen network which will reduce the ability of water to induce 
crystallization due to self-association. On the other hand, for Type 
IIIA lipid system, {Miglyol 812/Imwitor 988}-Cremophor RH40 at a 
ratio of 70(60/40)30, DMY was able to remain in a super-saturated 
state up to 24 h after emulsification (fig. 4). The crystallization of DMY 
from this system was also found to take up to 5 d to reach equilibrium. 
Unlike the limited crystallization which occurred at equilibrium from the 
self-micro-emulsified type II lipid-system (fig. 4), approximately 42% of 
the initial DMY dose (40 mg) precipitated out from the Type IIIA system. 
This might by due to two factors, one of which is the amount of DMY 
which the hydrophilic surfactant (Cremophor RH40) was contributing to 
its solubilization within the formulation.  
The amount of solubilized DMY within the pre-concentrate mixture 
which is contributed by the hydrophilic surfactant can be calculated 
using the following equation:  
S total  = FA X SA+FB X SB+FC X SC
where S 
 (Eq. 2) 
total  is the total solubility of DMY in the lipid mixture, FA, FB 
and FC;  mole fraction of each lipid excipient in the oil system, and 
SA, SB and SC;  
In the case of {Miglyol 812/Imwitor 988}-Cremophor RH40 system 
at ratio of 70(60/40)30, an amount of approximately 19 mg of DMY 
is solubilized within 1g of the oil mixture due to the contribution of 
Cremophor RH40. On emulsification of 1g formulation containing 
around 40 mg DMY in 100 ml of water, Cremophor RH40 which has 
a concentration of 30% w/w in the pre-concentrate, parts from the 
oil during dispersion and becomes diluted in the aqueous phase 
making a final concentration of 0.3% w/v. By applying the linear 
regression equation for Cremophor RH40 system presented in fig. 5 
which relates the increase of DMY solubility in Cremophor RH40-
water system as a function of surfactant concentration, we can work 
out the amount of DMY that the surfactant can maintain in solution 
after the dispersion of the formulation. The dissolved surfactant in 
the aqueous phase after dispersion can maintain an amount of 
around 5 mg of DMY in solution out of the 19 mg which Cremophor 
RH40 is responsible for in the initial pre-concentrate dose. 
Therefore, approximately 14 mg of DMY (≈ 35% of initial dose) will 
tend to come out of solution at equilibrium as a result of diffusion of 
the hydrophilic surfactant into the aqueous phase after dispersion. 
Another important factor which might further initiate crystallization 
of DMY from Type IIIA lipid system is the large surface available for 
contact with water due to the formation of very fine oil particles 
after dispersion. In the case of the very hydrophilic Type IIIB lipid 
system, the risk of precipitation is greater as the formulation 
contains a higher proportion of hydrophilic components 
(hydrophilic surfactants and/or water-soluble cosolvents). This is 
demonstrated by the instant crystallization of DMY from the Imwitor 
988/Cremophor RH40-PEG 400 Type IIIB lipid system depicted in 
fig. 4 Almost 70% of an initial DMY dose of ≈ 4 0 mg came out of 
solution in the first hour after the dispersion of the formulation. The 
amount of DMY that is dissolved within the lipid mixture due to the 
contribution of Cremophor RH40 or PEG 400 is around 23 or 12 mg, 
respectively. This means that the hydrophilic components in the 
Imwitor 988/Cremophor RH40-PEG 400 system are responsible for 
the respective DMY solubility in each constituent.  
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solubilizing approximately 35 mg of DMY in the lipid matrix. 
Cremophor RH40 and PEG 400 can keep up to only 5 mg of DMY in 
solution after the dispersion of the formulation as they tend to lose 
their solvent capacity on dilution with water. Therefore, 30 mg of 
DMY, which is almost equivalent to 75% of DMY initial dose, is 
expected to come out of solution after the emulsification. This is, 
however, in full agreement with the solubilization profile of DMY 
from this system which is depicted in fig. 4.  
The partition coefficient (log P) of the drug is an important 
physicochemical factor which influences the formulation design for 
lipid systems. Generally, drugs with log P values<2 are the most 
difficult drugs as they have limited solubility in both water and lipid. 
Therefore, it is unlikely that lipid formulation will be of value for such 
compounds [3]. On the other hand, more hydrophobic drugs may have 
good permeability to lipid membranes but dissolve very slowly in the 
lumen of the gut. Hydrophobic drugs with intermediate log P [2-4] 
may benefit the most from the formulation design of lipid-based 
systems. Hydrophilic surfactants and/or water-soluble cosolvents can 
be blended with the lipid systems to increase the solvent capacity of 
the formulation for molecules with intermediate log P. Yet, the choice 
between the different types of lipid-based formulations (Type I, II or 
III) has to be made considering the risk of drug precipitation and also 
the desirability of rapid absorption. Furthermore, drugs with log P>2 
are likely to be solubilized by bile salt micelles during digestion which 
in effect might prevent the drug from precipitation in the gut. Drugs 
with log P>5 can also benefit from the reformulation with lipid 
systems yet digestion by lipolysis will be crucial for the absorption of 
these drugs. The natural process of digestion offers the possibility that 
highly lipophilic drugs with log P values greater than 5 and triglyceride 
solubility of at least 50 mg/ml are preferentially transported via 
lymphatic route [27-28]. Lymphatic transport may be enhanced by 
lipid-based formulations yet the enhancement depends on the nature 
of the vehicle. According to a study by Porter et al. [29], the rate and 
extent of lymphatic transport of a highly lipophilic drug was of the 
following rank order; micellar>emulsion>lipid solution. 
Effect of oil-cosurfactant ratio on the solvency of dispersions  
As it was demonstrated by Hasan et al. [17-18], oil-cosurfactant ratio in 
the pre-concentrate mixture is an important parameter which 
determines the droplet size of the resultant emulsion. Nevertheless, in 
the case of hydrophilic surfactants with high solubilization capacity such 
as Cremophor RH 40 or EL, oil-cosurfactant ratio becomes also a crucial 
factor in affecting the kinetics of drug crystallization after the dispersion 
of the oil-system. This becomes more evident in the case of high 
hydrophilic lipid formulations and in particular, when water-miscible 
cosolvent is included in the system. By increasing the oil fraction in oil-
cosurfactant blend, we increase the non-polar hydrocarbon regions 
which interfere with water's hydrogen bonding network. As a result, 
water's ability to “squeeze out” non-polar compounds is reduced and 
hence the rate of crystallization is retarded. 
Fig. 6 to 9 display the effect of oil-cosurfactant ratio in Miglyol 
812/Imwitor 988-Cremophor RH40 system containing increasing 
concentration of PEG 400 on the solubilization behaviour of DMY 
after aqueous dispersion. For Miglyol 812-Imwitor 988 at ratios of 
1:9 and 3:7 without PEG 400, gradual loss of DMY solubility was 
observed (fig. 6 and 7, respectively). Yet, in the case of 5:5 system 
(without PEG 400), DMY was maintained in supersaturated state for 
up to 24h from the initial event of emulsification (fig. 8). However, 
the inclusion of PEG 400 at only 10-20% (w/w) in these systems 
accelerated DMY precipitation. There had been progressive drop in 
the solubility of DMY due to drug crystallization as the concentration 
of PEG 400 in the formulation was increased. The dissolved amount 
of DMY within the pre-concentrate mixture is enhanced as more 
cosolvent is used in the system. On dispersion of the formulation and 
due to loss of solvent capacity as hydrophilic components diffuse 
into the aqueous phase, crystallization of DMY occurs depending on 
the extent the cosolvent was contributing to its solubilization within 
the oil mixture, see table 4.  
For Miglyol 812-Imwitor 988 (1:9) or (3:9) systems at 10% or 20% 
PEG 400, more than half of the drug precipitated within the first 6h 
(table 4), which suggests that precipitation from SEDDS containing a 
cosolvent is likely to occur within the lumen of the gut. In contrast, 
when the Miglyol 812 content was further increased in the oil blend 
as in (5:5) system, only 10 and 30% of the DMY dose came out of 
solution in the case of inclusion either 10 or 20% PEG, respectively 
(table 4). Therefore, by increasing the weight fraction of Miglyol 812 
in the oil-cosurfactant blend, the solvency of the lipid system to 
maintain the drug in solution after the dispersion of the formulation 
is enhanced and consequently, precipitation is retarded, see fig. 9. 
Furthermore, the effect of including water-miscible cosolvent in 
Type II self-micro-emulsified lipid system, which is composed of 
water insoluble materials, on the crystallization of DMY after 
emulsification was also investigated and presented in fig. 10. The 
solubilization profiles of DMY observed from Miglyol 812/Imwitor 
988 (7:3)-Tagat TO system with and without any cosolvent have 
shown similar trend to the Miglyol 812/Imwitor 988 (5:5)-
Cremophor RH40 system (fig. 10 and 8, respectively). The inclusion 
of 10% PEG in the system did not influence the solubilization 
behaviour of DMY yet, around 25% of the drug precipitated after 6h 
from dispersion when 20% PEG was included in the pre-concentrate 
(fig. 10). The migration of the cosolvent into the aqueous phase and 
large surface area of contact with water due to the formation of fine 
dispersion are the two main factors which affect the crystallization 
of DMY in this system. Fig. 11 displays the effect of inclusion various 
cosolvents in the Miglyol 812/Imwitor 988 (5:5)-Cremophor RH40 
system on the solubilization behaviour of DMY after the dispersion 
of the formulation. The solubilization profiles of DMY were 
comparable for oil systems containing either PEG 400 or Ethanol. On 
the other hand, in the case of using transcutol or glycofurol, almost 
equivalent profiles were also obtained yet with relatively high 
crystallization rate vis-à-vis formulations containing PEG 400 or 
Ethanol. This is attributed to the high solubilization power of these 
cosolvents as they are able to dissolve more DMY within the lipid 
formulation which tend to crystallize on dispersion. 
 
 
Fig. 6: Effect of inclusion increasing concentration of PEG 400 in the miglyol 812/Imwitor 988-cremophor RH40 {70(10/90)30} system on 
the solubilization behaviour of DMY after aqueous dispersion. Bars represent standard errors (n = 3) 
Hasan et al. 




Fig. 7: Effect of inclusion increasing concentration of PEG 400 in the Miglyol 812/Imwitor 988-cremophor RH40 {70(30/70)30} system on 
the solubilization behaviour of DMY after dispersion in water. Bars represent standard errors (n = 3) 
 
 
Fig. 8: Effect of inclusion increasing concentration of PEG 400 in the Miglyol 812/Imwitor 988-cremophor RH40 {70(50/50)30} system on 
the solubilization behaviour of DMY after aqueous dispersion. Bars represent standard errors (n = 3) 
 
 
Fig. 9: The effect of oil-cosurfactant ratio in the pre-microemulsion concentrate of Miglyol 812/Imwitor 988-Cremophor RH40 at 
increasing concentration of PEG 400 on the solubilization of DMY after 6h from the emulsification event. 1g of each formulation 
containing approximately 40 mg DMY was allowed to emulsify in 100 ml water at 37 °C for 15 min bars represent standard errors (n = 3) 
Amount of DMY in solution (mg)
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Table 4: The effect of oil-cosurfactant ratio on the crystallization of DMY from the Miglyol 812/Imwitor 988-cremophor system containing 
various percentages of PEG 400 (Miglyol 812 is used as oil, Imwitor 988 as a cosurfactant and cremophor RH 40 is the hydrophilic surfactant) 
 Oil: cosurfactant 1:9 3:9 5:5 
PEG 400 % (w/w) Amount of precipitated DMY after 6h from dispersion (mg) 
0 6.88±0.54 3.72±0.61 ≈ 0 
10 21.95±2.4 13.94±3.44 4.32±0.17 
20 28.58±0.91 24.54±0.53 12.88±3.14 
*Each value represents mean±SD (n=3). 
 
 
Fig. 10: Effect of inclusion increasing concentration of PEG 400 in type II self-micro-emulsified lipid system (Miglyol 812/Imwitor 988-
Tagat TO) on the solubilization behaviour of DMY after dispersion in water. Bars represent standard errors (n = 3) 
 
 
Fig. 11: Effect of inclusion water-soluble cosolvents with various solubilization powers (σ) in the Miglyol 812/Imwitor 988 (5:5)-
Cremophor RH40 system on the solubilization profiles of DMY. Bars represent standard errors (n = 3) 
 
Effect of the ionic strength of Emulsification media  
In order to establish better in vitro-in vivo correlations for the oral 
administration of poorly water-soluble drugs, the composition, 
volume and hydrodynamics of the contents in the gastrointestinal 
lumen following the administration of the dosage form need to be 
accurately simulated [30]. Four media have been developed to 
simulate composition of the gastric and intestinal contents before 
and after ingested meal. Simulated Gastric Fluid (SGF) is used to 
simulate fasted gastric conditions, homogenized long-life milk (3.5% 
fat, pH 6.5) has been suggested to simulate fed state stomach, FaSSIF 
and FeSSIF to model fasted and fed state conditions in the small 
intestine, respectively.  
In this study the effect of FaSSIF and FeSSIF media on the 
solubilization behaviour of DMY from Type II and Type III lipid class 
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systems were investigated. In order to establish the importance of 
the bile salt-lecithin mixed micelles in the kinetics of drug 
crystallization from these systems, FaSSIF medium was prepared 
without bile salt and lecithin, see table 2. This will give us an insight 
into the solubilization capacity of the endogenous surfactants and 
moreover will address the effect of electrolytes on the solvency of 
these lipid systems after dispersion.  
Fig. 12 depicts the crystallization of DMY from Miglyol 812/Imwitor 
988 (7:3)-Tagat TO system after the emulsification in water or 
FaSSIF medium without bile slats-lecithin mixed micelles. As this fig. 
shows, the emulsification of this system in FaSSIF accelerated the 
crystallization of DMY. At equilibrium which took up to 5 d to reach, 
around 15% of drug precipitated when the system was emulsified in 
water in comparison with 35% in the case of FaSSIF. The effect of 
electrolytes on the emulsification behaviour of this system without 
drug was thoroughly studied in by Hasan et al. [17]. Generally, 
electrolytes reduce the hydrophilicity of the non-ionic surfactants 
and hence they become more soluble in the oil phase. This will cause 
depression in the phase inversion temperature (PIT) of the system 
and eventually and phase separation. This effect will depend on the 
inclusion of high polar oil in the formulation like Imwitor 988 and 
moreover, the use of non-ionic surfactant with relatively low HLB 
such as Tagat TO. In this case, the reduction in the HLB of the 
surfactant incurred by the presence of electrolytes in the 
emulsification media will be sufficient to cause shift in its solubility 
from the aqueous to the oil phase which results in phase separation 
and eventually crystallization of the dissolved drug. However, for 
Miglyol 812/Imwitor 988 (7:3)-Tagat TO phase separation was not 
seen yet, there had been substantial increase in the droplet size due 
to the shift in Tagat To solubility. Nonetheless, total phase 
separation was observed after the dispersion in FaSSIF by including 
more Imwitor 988 in the oil blend as in the case of Miglyol 
812/Imwitor 988 (6:4)-Tagat TO.  
It is expected that the use of surfactant systems with high HLB value 
such as, Cremophor RH40 or EL will not be affected by the ionic 
strength of the emulsification media as the reduction in the surfactant 
HLB is not sufficient to induce phase separation. This was evident from 
the crystallization profiles of DMY from Miglyol 812/Imwitor 988 (5:5)-
Cremophor system depicted in fig. 13. Almost comparable trends were 
observed from the emulsification in water or FaSSIF. In both media more 
than 40% of DMY came out of solution at equilibrium, vis-à-vis 15% in 
the case of Miglyol 812/Imwitor 988 (7:3)-Tagat TO when emulsified in 
water (fig. 12). This is attributed to the fact that the former system 
contains a hydrophilic surfactant that tends to lose its solvent capacity 
after the dispersion.  
As depicted in fig. 12 and 13 both formulations can take up to 5 d to 
reach equilibrium and that the drug can remain in a supersaturated state 
for up to 24h after the initial emulsification event. It could be argued that 
such products are unlikely to cause precipitation of the drug before the 
drug is absorbed and moreover, super-saturation might enhance 
absorption by increasing the thermodynamic activity of the drug [3]. 
 
 
Fig. 12: Effect of ionic strength of the emulsification media on the crystallization of DMY as function of time from Type II self-micro-
emulsified lipid system which contains water insoluble materials (Miglyol 812/Imwitor 988-Tagat TO 70(70:30)30). FaSSIF medium was 
used here without the bile salt-lecithin mixed micelles; see the text for further elaboration. Bars represent standard errors (n = 3) 
 
 
Fig. 13: Effect of ionic strength of the emulsification media on the crystallization of DMY as function of time from Type III self-micro-
emulsified lipid system which contains a hydrophilic surfactant with relatively high HLB value (Miglyol 812/Imwitor 988-Cremophor 
RH40 70(50:50)30). Bars represent standard errors (n = 3) 
Hasan et al. 
Int J App Pharm, Vol 11, Issue 1, 2019, 61-73 
 
70 
The effect of bile salt-lecithin mixed micelles 
In the small intestine, drug solubility can be enhanced by the 
secretion of bile salts and other endogenous amphiphilic biliary 
components including lecithin and cholesterol. At concentrations 
higher than critical micelle concentration (CMC) these substances 
form mixed micelles which can enhance the solubilization capacity 
of the GI tract. Solubilization enhancement into simple bile salt 
micelles has been reported for many lipophilic compounds [31]. Up to 
100-fold increase in solubility has been observed upon addition of bile 
salts at physiological concentrations to aqueous media. Moreover, 
Dissolution rate for many lipophilic compounds was substantially 
improved in the presence of bile salts. Improve the wetting was the 
predominant mechanism for substances at log P values in the range of 
1-2. However, in the case of highly lipophilic compounds such as 
danazol (log P 4.53), the increase in powder dissolution rate was 
attributed to the solubilization enhancement [32]. 
On the other hand, bile salt-lecithin mixed micelles was found to 
further enhance the solubility of lipophilic compounds [33-35]. 
Addition of lecithin causes an increase in the molecular weight of 
micelles from 6000to 150,000 Dalton [36] and hence more molar 
volume could be included into the palisade layer of the micelle. The 
extent of solubilization was shown to be influenced by the ratio of 
bile salts to lecithin [37]. Nonetheless, at high mixed micelles 
concentration enormous increase of the micellar diameter occurs. 
Therefore, a consequence of drug solubilization within micelles is a 
decrease in the apparent diffusion coefficient [38], since the effective 
diffusivity will be that of the micelle rather than of the drug 
monomer.  
Mithani et al. [39] studied the solubilization of a range of drugs by 
taurocholate solutions, and based on the drug log P and aqueous 
solubility developed good predictive estimates of the solubilization 
enhancement by bile salts. A linear correlation (Eq. 5) was observed 
between the logarithm of the solubilization ratio (SR), and log P. 
[SR] = 0.64 X log [P]+2.09 (Eq. 3) 
Solubilization ratio (SR) can be defined as the ratio between the 
solubilizing capacity of bile salt micelles (SCbs) measured as moles 
drug/mole taurocholate and the solubilization capacity in water (SCaq). 
According to this model, the process of solubilization is entirely driven 
by the hydrophobicity of the drug. Yet, in addition to partitioning 
behaviour other factors such as, the drug molecular weight or shape, and 
the affinity for bile salt micelles can also play a role. 
  
 
Fig. 14: Effect of bile salt-lecithin mixed micelles on the solubilization capacity of Miglyol 812/Imwitor 988-Tagat TO {70(70/30)30} system after 
dispersion. 1g of each formulation containing approximately 40 mg DMY was allowed to emulsify in 100 ml FaSSIF (without bile salt mixed 
micelles) or FeSSIF medium which contained 15 mmol NaTC/3.75 mmol lecithin mixed micelles. Bars represent standard errors (n = 3) 
 
 
Fig. 15: Effect of bile salt-lecithin mixed micelles on the solubilization capacity of miglyol 812/Imwitor 988-Tagat TO {70(60/40)30} 
system after dispersion in various emulsification media. Bars represent standard errors (n = 3) 
Solubility of DMY (mg/ml)
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Fig. 16: Effect of bile salt-lecithin mixed micelles on the solvency of class IIIA lipid system containing a water-soluble cosolvent (Miglyol 
812/Imwitor 988-Cremophor RH40-Ethanol 50(50/50)30/20) after dispersion in water or FeSSIF. Bars represent standard errors (n = 3) 
 
Data obtained by Solomon et al. [40] for a range of steroids 
confirmed that shape is a factor which clearly can influence the 
extent of solubilization as the spatial orientation into the micelles 
available to the drug is limited. Long-chain esters of hydrocortisone 
such as hydrocortisone caprylate whilst being hydrophobic with log 
P 7.82 could not be incorporated into the micelles as efficiently as 
progesterone which is less hydrophobic (log P 4.22) and therefore, 
solubilization enhancement was found to be far more less in the 
former. Furthermore, the higher affinity of bile salt micelles for 
indomethacin as compared to phenylbutazone could not be 
explained on the basis of lipid solubility and molal volume. The 
lower interaction of phenylbutazone with bile salts was attributed to 
repulsion forces due to its carbon acid [41]. 
Fig. 14-16 depict the effect of various emulsification media on the 
solubilization behaviour of DMY from Type II and III lipid-class 
systems. For this study, FaSSIF medium was used without bile salt-
lecithin mixture while FeSSIF contained mixed micelles of 15 mmol 
sodium taurocholate (NaTC)/3.75 mmol lecithin. For Miglyol 
812/Imwitor 988 (7:3)-Tagat TO system, there was no significant 
difference in the solubilization profiles of DMY in FaSSIF vis-à-vis 
FeSSIF media for the first 6h from the emulsification event, see fig. 
14. This is because loss of solvent capacity of the resultant 
dispersion in FaSSIF medium started to occur significantly 24h 
aftermath emulsification. Therefore, the effect of NaTC/lecithin 
mixed micelles in the solubilization enhancement of DMY could not 
be discerned. Nevertheless, the solubilization behaviour of DMY 
from Miglyol 812/Imwitor 988 (6:4)-Tagat TO system was 
substantially influenced by emulsification in FaSSIF media, fig. 15. As 
was previously elaborated, gradual phase separation was observed 
after the dispersion of the former system in FaSSIF. Formation of an 
oil layer that is rich with hydrophobic surfactant and increasing 
amounts of dissolved DMY continued to develop on the top of the 
aqueous phase which contained few dispersed oil droplets. As a 
result, there had been drop in DMY solubility progressively with 
time after emulsification in FaSSIF. After 24h from the emulsification 
event and due to oil separation, almost 75% drop of the initial DMY 
solubility was observed. However, when the emulsification medium 
contained bile salt-lecithin mixed micelles to stimulate the intestine 
at fed state as in FeSSIF, the resulting dispersion was able to keep 
DMY in solution almost up to 24h after dispersion, see fig. 15. This 
increase in DMY solubility is attributed to the enhancement of oil 
solubilization within the bile salt micellar system. Similarly, as 
depicted in fig. 16, in contrast to the loss of solvent capacity of 
Miglyol 812/Imwitor 988-Cremophor RH40 system containing 20% 
w/w Ethanol after dispersion in water, the emulsification in FeSSIF 
maintained the solubility of drug in solution. This indicates the 
capacity of NaTC/lecithin mixed micelles to prevent the drug from 
precipitation in the lumen of the gut during digestion of lipid 
formulation. Despite the claim that the absorption of Cyclosporin A 
‘Sandimmune Neoral’ is less affected by bile flow and pancreatin 
[42], it is anticipated that the role of mixed micelles must become 
evident in the pharmacokinetics of Neoral whereby, at least a single 
oral dose of 200 mg might be needed. Therefore, there is an 
immense need for practical methods to predict the fate of drugs 
after the dispersion of lipid systems in the GI tract. 
It is worth noting here that loss of solvent capacity for all 
dispersions in FeSSIF was only observed 24h aftermath 
emulsification which might reflect the in-stability of mixed micelles 
with time. Yet, it is evident that the efficiency of dissolution and 
absorption for lipophilic compounds with log P>2 are probably 
better in the fed state than fasted. In a study by Charman et al. [43] 
in healthy human volunteers showed that both peak concentration 
and area under the curve were about three times higher when 
danazol was administered in fed than fasted conditions. 
CONCLUSION 
The bioavailability enhancement of most oral lipid-based formulations 
depends on the ability of the oil vehicle to maintain the drug in 
solution after dispersion. Solvency of emulsions formed by self-
emulsifying drug delivery system is an important parameter 
influencing the fate of dissolved drug after dispersion of the 
formulation. Physicochemical factors which determine the solvent 
capacity of these emulsions such as, hydrophilicity of lipid system, 
droplet size of the resultant dispersion, log P of drug, ionic strength of 
the emulsification media and the bile salt-lecithin mixed micelles were 
sought for investigating the tendency of drug to precipitate after 
administration of an oily vehicle. In vitro methods, however, were used 
in this study in order to investigate the solubilization behaviour of the 
drug from dispersions formed by Type II and Type III lipid class systems 
in an attempt to predict the dynamic changes, which are expected to 
occur in the gut. Nonetheless, there is a clear need for developing 
methods for tracking the solubilization state of the drug in vivo. 
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